Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center.

We observed that EFG was safe and modified significantly the course of the disease along a 14-month follow-up. Our experience strengthens the role of FcRn inhibition as an effective new tool for long-term treatment of gMG.